All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Neladalkib Showcases Early Activity in ALK+ Solid Tumors

October 27th 2025

Neladalkib showed durable responses and good tolerability in ALK-positive solid tumors, including TKI-pretreated patients, in early ALKOVE-1 results.

ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

October 27th 2025

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Gedatolisib-Based Regimens May Advance PIK3CA Wild-Type Metastatic Breast Cancer Care

October 27th 2025

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

Five Under 5: Top Oncology Videos for the Week of 10/19

October 26th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma

October 26th 2025

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC

October 25th 2025

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC

October 24th 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia

October 24th 2025

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Toripalimab Becomes First Approved Immunotherapy for Recurrent Unresectable/Metastatic NPC in Canada

October 24th 2025

Toripalimab has been approved by Health Canada both as monotherapy and in combination with cisplatin and gemcitabine for recurrent or metastatic NPC.

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab in NRG1+ Cholangiocarcinoma

October 24th 2025

Zenocutuzumab has received BTD from the FDA for patients with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.

Chemotherapy Combination Boosts Overall Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

October 24th 2025

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

IMvigor011 Confirms ctDNA Status as Key Predictor of Adjuvant Atezolizumab Efficacy in MIBC

October 24th 2025

Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

International Medical Graduates Produce Significant Research Contributions During Hematology/Oncology Fellowship

October 24th 2025

Arya Mariam Roy, MD, MBBS, discusses a study of the research productivity of hematology/oncology fellows who are international medical graduates.

Saruparib Plus an ARPI Shows Activity, Tolerability in Metastatic Prostate Cancer

October 24th 2025

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

FDA Approval of Y-90 Resin Microspheres Marks a New Chapter for Radioembolization in Unresectable HCC

October 23rd 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

Shorter Duration of Chemotherapy Associated With Improved PROs in Advanced Urothelial Cancer

October 23rd 2025

Three cycles of platinum-based chemotherapy yielded superior PROs vs 6 cycles in advanced urothelial cancer.

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer

October 23rd 2025

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

Biomarker Analysis Reveals Clues to Long-Term Survival in Glioblastoma Patients Treated with SurVaxM

October 23rd 2025

A study led by Roswell Park researchers zeroes in on why some newly diagnosed glioblastoma patients survive longer than others after standard treatment plus SurVaxM.